Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) is a clinical-stage biopharmaceutical company. It uses Artificial Intelligence (“AI”) to develop drugs for non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, liver cancer (“HCC”), and other chronic diseases.
About Hepion’s Main Drug
The Company’s main drug, Rencofilstat, is a powerful cyclophilin inhibitor that can affect many disease processes. As per the company, the Rencofilstat drug has demonstrated its ability to decline liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models. Now, this drug is in Phase 2 clinical trials for NASH treatment.
Moreover, the FDA gave Rencofilstat Fast Track status for NASH treatment in November 2021 and Orphan Drug status for HCC treatment in June 2022. Furthermore, the company also illustrated that Hepion has developed a proprietary AI/ML platform. It can better understand disease processes and identify patients who will respond to rencofilstat.
This AI/ML could potentially reduce its development time and increase the observable effects of rencofilstat compared to placebo. Moreover, Hepion’s AI/ML can be used to support its ongoing NASH and HCC clinical trials and discover other potential therapeutic uses for rencofilstat as a cyclophilin inhibitor.
HEPA announced that in their new research study in mice, its main drug stopped the growth of liver tumors caused by chronic infection with the human hepatitis C virus (“HCV”).
The company shared that they compared rencofilstat to two anti-HCV drugs, sofosbuvir, and velpatasvir, which are very effective at killing HCV. All three drugs started at week 16 and cleared HCV infection.
However, only rencofilstat reduced tumors at week 30. Sofosbuvir and velpatasvir -treated mice had the same large tumors as mice that got no drugs, while rencofilstat -treated mice had 80% smaller tumors.
Furthermore, Hepion recently announced a new innovative way that rencofilstat stops cancer in liver cancer and the drug’s anti-cancer effect in many cell lines for 86% of cancer types.
How This Drug Can be a Catalyst For its Share Price to Rise?
This information is shared for the public interest and it can increase the demand for HEPA shares as investors may see the potential of rencofilstat as a breakthrough treatment for the diseases. This could boost the revenue and profitability of Hepion in the future, and increase its market value.
The company could also attract more attention from the scientific and medical. This could increase the visibility and credibility of Hepion as a probable emerging leader in AI-driven drug discovery and development.
Since the stock has been investing in innovation and research, its earnings for the quarter could show the results of its strategic initiatives and growth potential. This could improve its outlook and valuation.
Furthermore, this could enhance the reputation and recognition of Hepion, and generate interest from potential partners, collaborators, and customers. This could also increase the awareness and demand for HEPA shares, and raise its stock price.
What Patterns Does the HEPA Chart Highlight?
Now, it seems like the stock is primed and geared for a remarkable rally, as it has been building a bullish pattern known as a falling wedge in the longer trend. This might gather the bull’s power to break the resistance level and soar to new elevations from the current base zone.
Therefore to incline upwards the price needs to accumulate more bull buying power in the longer trend.
Moreover, if buyers boost more the HEPA stock might surge strongly from the current level and surge above the parallel channel. The possible targets are between $5.00 and $6.00.
On the contrary, if HEPA stock fails to hold its grip and declines and breaches below $3.00, then it may hit $2.00.
Currently, HEPA stock is trading below the 20, 50, 100, and 200 EMAs. This is rejecting the price as the stock faced massive consequences led by negative streaks of earnings reports. This stretched the HEPA stock price downtrend for a prolonged period of time.
Nevertheless, if buying volume increases, the price might support bullish momentum by making higher highs and lows. Hence, the HEPA price is expected to move upward giving a bullish outlook over the daily time frame chart.
Summary
The Company’s main drug, Rencofilstat has demonstrated its ability to act against liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models. It illustrated that Hepion has developed a proprietary AI/ML platform. This AI/ML can potentially reduce its development time and increase the observable effects of rencofilstat compared to placebo. Furthermore, Hepion recently announced a new innovative way that rencofilstat stops cancer in liver cancer.
This information is shared for the public interest and it can increase the demand for HEPA shares This could boost the revenue and profitability of Hepion in the future, and increase its market value. Moreover, this could increase the visibility and credibility of Hepion as a probable emerging leader in AI-driven drug discovery and development.
Furthermore, this could enhance the reputation and recognition of Hepion and increase the awareness and demand for HEPA shares, and raise its stock price.
Technical Levels
Support Levels: $3.00 and $2.00
Resistance Levels: $5.00 and $6.00
Disclaimer
In this article, the views, and opinions stated by the author, or any people named are for informational purposes only, and they don’t establish the investment, financial, or any other advice. Trading or investing in cryptocurrency assets comes with a risk of financial loss.
Andrew is a blockchain developer who developed his interest in cryptocurrencies while his post-graduation. He is a keen observer of details and shares his passion for writing along with being a developer. His backend knowledge about blockchain helps him give a unique perspective to his writing
Source: https://www.thecoinrepublic.com/2023/11/10/could-hepion-pharmaceuticals-count-among-the-best-investments/